Tabitha Salzer
Psychiatric/Mental Health · Tucson, AZNPI 1699319939
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,126 of the $19,749 with a category attached, or 66.5%. 23 manufacturers reported payments, led by AbbVie at 42.3% of the total. 2025 is the largest year on record at $10,716, 8.7 times the $1,233 reported in 2021. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $35.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Alkermes, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $4K from 17 others
What the payments were for
- Consulting fees$7404%
- Speaking & faculty fees$5,40027%
- Travel & lodging$3012%
- Food & beverage$13,12666%
- Education$1811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $8,355 |
| Alkermes, Inc. | 66 | $1,954 |
| E.r. Squibb & Sons, L.L.C. | 18 | $1,616 |
| Neurocrine Biosciences, Inc. | 39 | $1,437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,382 |
| Teva Pharmaceuticals USA, Inc. | 39 | $1,138 |
| Johnson & Johnson | 22 | $766 |
| Otsuka America Pharmaceutical, Inc. | 30 | $647 |
| Axsome Therapeutics, Inc. | 20 | $580 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $447 |
| Indivior Inc. | 18 | $321 |
| Vanda Pharmaceuticals Inc. | 13 | $258 |
| Sunovion Pharmaceuticals Inc. | 11 | $178 |
| Bausch Health US, LLC | 7 | $147 |
| AstraZeneca | 1 | $125 |
| Brainsway USA Inc | 1 | $103 |
| Lundbeck LLC | 4 | $80 |
| Corium, LLC | 4 | $75 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Almatica Pharma LLC | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Lilly USA, LLC | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$5,992
- LYBALVI$1,435
- ARISTADA$500
- CAPLYTA$262
- VIVITROL$250
- Auvelity$247
- COBENFY$128
- ARISTADA INITIO$125
- FASENRA$125
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- SPRAVATO$121
- INVEGA$121
- REXULTI$120
- Austedo XR$116
- ABILIFY MYCITE$114
- Brainsway Deep TMS$103
How this compares
$19,749 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PerserisRisperidone | 19 | $58,556 |
| Invega SustennaPaliperidone Palmitate | 14 | $51,489 |
| Abilify MaintenaAripiprazole | 20 | $50,954 |
| Risperdal ConstaRisperidone Microspheres | 20 | $26,046 |
| VraylarCariprazine Hcl | 11 | $14,917 |
| Divalproex Sodium | 91 | $8,644 |
| Divalproex Sodium ErDivalproex Sodium | 22 | $4,035 |
| Paliperidone ErPaliperidone | 20 | $3,097 |
| Duloxetine Hcl | 25 | $3,087 |
| Risperidone | 105 | $2,770 |
| Aripiprazole | 56 | $2,394 |
| Lamotrigine | 119 | $2,155 |
| Sertraline Hcl | 112 | $2,153 |
| Trazodone Hcl | 84 | $1,659 |
| Mirtazapine | 64 | $1,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $766 | $77,53434 claims |
| Indivior Inc.Perseris | $321 | $58,55619 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $647 | $50,95420 claims |
| AbbVieVraylar | $8,355 | $14,91711 claims |
| Almatica Pharma LLCSertraline Hcl | $36 | $2,153112 claims |
| Lilly USA, LLCOlanzapine | $21 | $54312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Tucson
- Aaron del PinoTucson$28K
- Daniel ChafetzTucson$18K
- John EkmanTucson$13K
- Cassandra Diaz de LeonTucson$10K
- Sylvia ValenzuelaTucson$9K
- Toyin MarcusTucson$8K
- Isabella WaszkiewiczTucson$8K
- Melanie MartinTucson$7K
- Justine ConfinoTucson$5K
- Elizabeth ElliottPhoenix$363K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.